Clinical Trial Update: Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating neoadjuvant and adjuvant nivolumab with BMS-813160, with or without GVAX, for locally advanced pancreatic ductal adenocarcinoma has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• BMS-813160
• GVAX Pancreas Vaccine
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED